Overturn rates are the closest thing denial management has to a direct performance indicator. They measure what the appeals process is producing — not how many appeals were filed, but how many came back in the hospital’s favor. The difference between a 40% overturn rate and a 70% overturn rate, across a denial inventory of any significant size, is millions of dollars.

For a broader framework, see denial management healthcare.

The Baseline Numbers

Industry benchmarks for denial overturn rates vary depending on methodology and population studied. HFMA’s revenue cycle benchmarking data places average overturn rates for appealed denials in the 40–60% range for standard commercial denials, with significant variation based on denial category and appeal quality. Clinical denials — medical necessity, level-of-care, DRG downgrade — tend to have lower average overturn rates when appeals are handled by generalist billing staff and higher rates when handled by clinical specialists.

The American Hospital Association has documented that a meaningful share of denied claims that go to appeal are ultimately overturned — suggesting that a substantial portion of payer denials are, in the AHA’s characterization, inappropriate. Many hospitals are writing off claims that could be recovered; the appeal process simply isn’t reaching them.

Where Overturn Rates Are Highest

Technical and administrative denials generally have the highest overturn rates when worked correctly. These are denials that resulted from correctable errors — missing information, billing discrepancies, authorization numbers that exist but were not included. When the correction is made and the claim is resubmitted or a simple appeal is filed, overturn rates can approach 80–90% for well-managed programs.

Clinical denials are more variable. Medical necessity denials have lower average overturn rates than administrative denials, but they are not uniformly difficult to overturn. Overturn rates on clinical appeals depend heavily on:

• The quality of the appeal — whether it specifically addresses the payer’s criteria and connects the patient’s clinical documentation to those criteria
• The expertise of the reviewer — licensed clinicians with payer policy knowledge consistently outperform generalist billing staff on clinical appeals
• The payer’s historical behavior — some payers have higher overturn rates on appeal than others, a pattern that experienced programs track
• The denial category — DRG downgrades and level-of-care denials have different overturn profiles than standard medical necessity denials

To understand how appeals are constructed, see clinical appeals healthcare.

The Payer Variable

Overturn rates vary significantly by payer. Commercial payers, Medicare Advantage plans, and Medicaid managed care organizations have meaningfully different overturn profiles — both at the claim type level and across appeal levels.

A Medicare Advantage plan that denies medical necessity at a high rate but overturns 65% of well-constructed appeals represents a different operational challenge than a commercial plan that denies less but overturns a lower share of appeals.

The Kaiser Family Foundation’s research on Medicare Advantage denial appeals found that a substantial proportion of denied claims that were appealed were ultimately overturned — indicating both that initial denial rates are inflated relative to actual non-covered care and that appeals programs produce material recoveries when they reach the right cases.

Organizations that track overturn rates by payer accumulate intelligence that changes their approach. Payers with higher overturn rates may warrant more aggressive appeal investment. Payers with lower overturn rates on specific denial types may require earlier escalation strategies.

The Multi-Level Appeal Curve

Overturn rates also vary by appeal level. First-level internal appeals — the initial formal response — show the broadest variation. Administrative denials often resolve quickly, while clinical denials require more structured arguments.

Second-level appeals, when available, typically show lower overturn rates because the easier cases were resolved at level one.

External independent review introduces another layer. Because these reviews are conducted by clinicians independent of the payer, they can produce higher overturn rates for certain clinical denial categories.

Understanding this progression helps organizations determine when escalation is appropriate and where to allocate resources.

What the Data Says About Appeal Quality

Across denial categories and payer types, one variable consistently predicts overturn rates more than any other: appeal quality.

The argument in the appeal letter, the documentation supporting it, and the policy citations included determine whether a reviewer has the material needed to make a favorable determination.

Generic appeals perform significantly worse than structured, evidence-based arguments. Appeals that directly connect clinical documentation to payer criteria consistently achieve stronger outcomes.

This explains why specialist-led programs outperform generalist billing teams, particularly for complex clinical denials.

Revecore’s documented 74% average overturn rate across its client base reflects what happens when clinical expertise, payer-specific policy knowledge, and AI-assisted record review are combined in a structured appeal process — rather than treating appeals as a volume exercise.

Turning Overturn Rates Into Strategy

Overturn rates are not just a reporting metric. They provide a roadmap for improving denial management performance.

Organizations that analyze overturn rates by denial type, payer, and appeal level gain insight into where recovery efforts are most effective.

They also identify which denial categories require additional expertise, stronger documentation, or different escalation strategies.

To improve upstream performance, see denial prevention healthcare.

Improving Overturn Rates Over Time

Improving overturn rates requires structured process, strong clinical expertise, and effective prioritization.

Organizations that invest in structured appeal development, payer-specific knowledge, and performance tracking achieve higher recovery rates.

They also reduce unnecessary write-offs and improve overall revenue cycle performance.

To strengthen overall strategy, see denial root cause analysis healthcare.

Turning Appeals Into Recovered Revenue

Denial overturn rates directly reflect how much revenue an organization recovers from denied claims. Improving those rates has an immediate financial impact.

Hospitals that strengthen appeal quality and align resources with high-value cases recover more revenue and reduce long-term losses.

For organizations looking to improve appeal performance and recovery outcomes, learn more about denial appeals services.